Harnessing technology to improve clinical trials: Study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 2004-2009

  Pietanza, M Catherine ^a   Basch, Ethan M ^a   Lash, Alex ^a   Schwartz, Lawrence H ^a   Ginsberg, Michelle S ^a   Zhao, Binsheng ^a   Shouery, Marwan ^a   Shaw, Mary ^a   Rogak, Lauren J ^a   Wilson, Manda ^a   Gabow, Aaron ^a   Latif, Marcia ^a   Lin, Kai Hsiung ^a   Wu, Qinfei ^a   Kass, Samantha L ^a   Miller, Claire P ^a   Tyson, Leslie ^a   Sumner, Dyana K ^a   Berkowitz Hergianto, Alison ^a   Sima, Camelia S ^a   Kris, Mark G ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PACLITAXEL; PEMETREXED;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER SYSTEM; CONTROLLED STUDY; COUGHING; DYSPNEA; EPIPHORA; EPISTAXIS; FATIGUE; FEMALE; HOARSENESS; HUMAN; IMAGE ANALYSIS; INFORMATION SCIENCE; INTERNET; KARNOFSKY PERFORMANCE STATUS; LUNG CANCER; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; OPEN STUDY; PAIN; PATIENT-REPORTED OUTCOME; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SELF REPORT; SOFTWARE; STOMATITIS; COMPUTER PROGRAM; DRUG SURVEILLANCE PROGRAM; LUNG TUMOR; MEDICAL INFORMATICS; METHODOLOGY; PATIENT; PHASE 2 CLINICAL TRIAL (TOPIC); QUESTIONNAIRE; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MEDICAL INFORMATICS; PATIENTS; QUESTIONNAIRES; SELF REPORT; SOFTWARE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880656074     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.8117     Document Type: Article

References (47)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715, 2004
2. Perrone F, Di Maio M, De Maio E, et al: Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncol 4:305-311, 2003
3. Mariani L, Marubini E: Content and quality of currently published phase II cancer trials. J Clin Oncol 18:429-436, 2000
4. El-Maraghi RH, Eisenhauer EA: Review of phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in phase III. J Clin Oncol 26:1346-1354, 2008
5. Michaelis LC, Ratain MJ: Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 13:2400-2405, 2007
6. Trotti A, Colevas AD, Setser A, et al: Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121-5127, 2007
7. Basch E, Artz D, Iasonos A, et al: Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 14:264-268, 2007
8. Basch E, Artz D, Dulko D, et al: Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 23:3552-3561, 2005
9. Zhao B, Schwartz LH, Moskowitz CS, et al: Lung cancer: Computerized quantification of tumor response—Initial results. Radiology 241:892-898, 2006
10. Basch E, Iasonos A, Barz A, et al: Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 25:5374-5380, 2007
11. Zhao B, Reeves A, Yankelevitz D, et al: Three-dimensional multi-criterion automatic segmentation of pulmonary nodules of helical CT images. Opt Eng 38:1340-1347, 1999
12. Zhao B, Schwartz LH, Jiang L, et al: Shape-constraint region growing for delineation of hepatic metastases on contrast-enhanced computed tomo-graph scans. Invest Radiol 41:753-762, 2006
13. Yan J, Zhao B, Wang L, et al: Marker-controlled watershed for lymphoma segmentation in sequential CT images. Med Phys 33:2452-2460, 2006
14. Pietanza MC, Kadota K, Huberman K, et al: Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 18:1138-1145, 2012
15. Janjigian YY, Azzoli CG, Krug LM, et al: Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 17:2521-2527, 2011
16. Drilon AEDC, Kyuichi K, Huberman K, et al: 5-day dosing schedule of temozolomide in relapsed sensitive or refractory small cell lung cancer (SCLC) and methyl-guanine-DNA methyltransferase (MGMT) analysis in a phase II trial. J Clin Oncol 30:464s, 2012 (suppl; abstr 7052)
17. Basch E, Bennett A, Pietanza MC: Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103:1808-1810, 2011
18. Basch E, Jia X, Heller G, et al: Adverse symptom reporting by patients versus clinicians: Relationships with clinical outcomes. J Natl Cancer Inst 101:1624-1632, 2009
19. Meacham R, McEngart D, O’Gorman H: Use and Compliance With Electronic Patient Reported Outcomes Within Clinical Drug Trials. Toronto, Ontario, Canada, International Society for Pharmaco-economics and Outcomes Research, 2008
20. Basch E: The missing voice of patients in drug-safety reporting. N Engl J Med 362:865-869, 2010
21. Basch EM, Reeve BB, Mitchell SA, et al: Electronic toxicity monitoring and patient-reported outcomes. Cancer J 17:231-234, 2011
22. McCann L, Maguire R, Miller M, et al: Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl) 18:156-164, 2009
23. Dy SM, Roy J, Ott GE, et al: Tell Us: A Web-based tool for improving communication among patients, families, and providers in hospice and palliative care through systematic data specification, collection, and use. J Pain Symptom Manage 42:526-534, 2011
24. Snyder CF, Jensen R, Courtin SO, et al: Pa-tientViewpoint: A website for patient-reported outcomes assessment. Qual Life Res 18:793-800, 2009
25. Abernethy AP, Herndon JE 2nd, Wheeler JL, et al: Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: Pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manage 37:1027-1038, 2009
26. Abernethy AP, Zafar SY, Uronis H, et al: Validation of the Patient Care Monitor (Version 2.0): A review of system assessment instrument for cancer patients. J Pain Symptom Manage 40:545-558, 2010
27. National Cancer Institute: Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Aug 2010. NCI Tools for Outcomes Research. http://outcomes.cancer.gov/tools/pro-ctcae.html
28. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
29. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
30. Schwartz LH, Ginsberg MS, DeCorato D, et al: Evaluation of tumor measurements in oncology: Use of film-based and electronic techniques. J Clin Oncol 18:2179-2184, 2000
31. Erasmus JJ, Gladish GW, Broemeling L, et al: Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response. J Clin Oncol 21:2574-2582, 2003
32. Awad J, Owrangi A, Villemaire L, et al: Three-dimensional lung tumor segmentation from x-ray computed tomography using sparse field active models. Med Phys 39:851-865, 2012
33. Franklin JD, Guidry A, Brinkley JF: A partnership approach for Electronic Data Capture in small-scale clinical trials. J Biomed Inform 44:S103-S108, 2011 (suppl 1)
34. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377-381, 2009
35. Linguraru MG, Richbourg WJ, Liu J, et al: Tumor burden analysis on computed tomography by automated liver and tumor segmentation. IEEE Trans Med Imaging 31:1965-1976, 2012
36. Moltz JH, D’Anastasi M, Kiessling A, et al: Workflow-centred evaluation of an automatic lesion tracking software for chemotherapy monitoring by CT. Eur Radiol 22:2759-2767, 2012
37. Nanthagopal AP, Rajamony RS: A region-based segmentation of tumour from brain CT images using nonlinear support vector machine classifier. J Med Eng Technol 36:271-277, 2012
38. Nelson EK, Piehler B, Eckels J, et al: LabKey Server: An open source platform for scientific data integration, analysis and collaboration. BMC Bioin-formatics 12:71, 2011
39. Maki RG, D’Adamo DR, Keohan ML, et al: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133-3140, 2009
40. Thwin SS, Clough-Gorr KM, McCarty MC, et al: Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol 7:23, 2007
41. Durkalski V, Wenle Z, Dillon C, et al: A web-based clinical trial management system for a sham-controlled multicenter clinical trial in depression. Clin Trials 7:174-182, 2010
42. Pozamantir A, Lee H, Chapman J, et al: Web-based multi-center data management system for clinical neuroscience research. J Med Syst 34:25-33, 2010
43. Lallas CD, Preminger GM, Pearle MS, et al: Internet based multi-institutional clinical research: A convenient and secure option. J Urol 171:1880-1885, 2004
44. Litchfield J, Freeman J, Schou H, et al: Is the future for clinical trials internet-based? A cluster randomized clinical trial. Clin Trials 2:72-79, 2005
45. Buchsbaum R, Kaufmann P, Barsdorf AI, et al: Web-based data management for a phase II clinical trial in ALS. Amyotroph Lateral Scler 10:374-377, 2009
46. Weisfeld N, English RA, Claiborne AB: Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary. Washington, DC, The National Academies Press, 2012
47. Kris MG, Meropol NJ, Winer EP: Accelerating Progress Against Cancer: ASCO’s Blueprint for Transforming Clinical and Translational Cancer Research. Alexandria, VA, American Society of Clinical Oncology, 2011